News & Media / Newsroom
Fondazione Golinelli organizined, on Saturday, February 17, a special day to pay tribute to Marino Golinelli, philanthropist, entrepreneur, researcher and art lover
Bologna, 31 January 2024, 22:01 CET – Alfasigma S.p.A. is pleased to announce the successful completion of the transaction to acquire the Jyseleca® (filgotinib) business from Galapagos NV (Euronext & NASDAQ: GLPG) for up to €170 million. This marks a significant milestone for the company’s international growth strategy and follows both the signing of the agreement announced on 2 January 2024 and of the Letter of Intent announced on 30 October 2023.
Alfasigma S.p.A today announced that it has signed an agreement with Galapagos NV (Euronext & NASDAQ: GLPG) to acquire the Jyseleca® (filgotinib) business for up to €170 million.
Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.
Bologna, Italy – November 8, 2023 — Alfasigma S.p.A. (“Alfasigma”) announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. (“Interstellar”), successfully completed its tender offer to purchase all outstanding shares of common stock of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (“Intercept”), at a price of USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes.
Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company headquartered in Italy, announced today that it has signed a letter of intent to acquire the Jyseleca® business from Galapagos (Euronext & NASDAQ: GLPG), a global biotechnology company headquartered in Belgium, developing transformational medicines in immunology and oncology.
Corporate Communication & Institutional Relations
Staff
[email protected] +39.051.6489.511Press Office
[email protected]You’re entering Alfasigma global website
I agree